ArticleDiscover oncology2026
EREG promotes colorectal cancer progression and immune suppressive microenvironment formation through IL-17A/NF-κB pathway.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC), as a common malignancy, predominantly exhibits an immune evasion phenotype, making it largely unresponsive to immune checkpoint inhibitors (ICIs). Epiregulin (EREG), a member of the epidermal growth factor family, is frequently overexpressed in CRC, which has been implicated in tumor progression and therapy resistance in various cancers, but its specific role and underlying mechanisms in CRC cell and tumor microenvironment (TME) regulation remain to be elucidated.
methodsWe determined EREG expression in CRC through The Cancer Genome Atlas (TCGA) database and selected tumor tissues and adjacent non-tumor tissues from 8 treatment-naïve patients with newly diagnosed advanced disease for immunohistochemical analysis(IHC). Lentivirus-mediated RNA interference was employed to establish EREG knockdown CRC cell lines. The effects of EREG silencing on cell proliferation, invasion, colony formation, migration, and apoptosis were evaluated by CCK-8 assay, transwell invasion assay, colony formation assay, wound healing assay, and flow cytometry, respectively. Furthermore, mRNA sequencing (mRNA-seq), enzyme-linked immunosorbent assay (ELISA), and Western blot (WB) analyses were conducted to explore intracellular signaling pathway changes and TME modulation following EREG knockdown.
resultsEREG was significantly overexpressed in CRC tissues compared to adjacent normal tissues and correlated closely with intratumoral CD8+T cell infiltration. EREG knockdown significantly inhibited CRC cell proliferation, invasion, clone and migration, while promoting apoptosis. Differentially expressed genes were enriched in the Interleukin-17A/Nuclear Factor Kappa B(IL-17A/NF-κB) signaling pathway. EREG depletion suppressed IL-17A and NF-κB expression, reversible by exogenous IL-17A. Additionally, EREG knockdown increased secretion of chemokines, enhancing CD8+T cell infiltration and remodeling the TME towards an immune-activated state.
conclusionEREG promotes CRC progression by modulating the IL-17A/NF-κB pathway and maintaining an immunosuppressive TME. Targeting EREG may improve immunotherapy outcomes by transforming cold tumors into hot tumors, providing a promising strategy for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.